<DOC>
	<DOCNO>NCT00989612</DOCNO>
	<brief_summary>This trial ass immunogenicity safety elicit adjuvanted GSK Biologicals ' influenza investigational vaccine GSK2340274A healthy Japanese adult age 20-64 year .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Safety Investigational Influenza Vaccine ( H1N1 )</brief_title>
	<detailed_description>This Protocol Posting update follow Protocol amendment 1 &amp; 2 , October 2009 . The section impact study design outcome measure</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Japanese male female adult 20 64 year age time first vaccination , inclusive . Good general health assess medical history physical examination Subjects investigator believe comply requirement protocol . Written inform consent obtain subject . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device . Females nonchildbearing potential may enrol study . Female childbearing potential may enrol study , : practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . History previous administration novel [ H1N1 ] v vaccine . Previous participation study NCT00742885 . Presence significant acute chronic , uncontrolled medical psychiatric illness . Presence evidence substance abuse neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence axillary temperature &gt; = 37.5 °C , acute symptom great `` mild '' severity schedule date first vaccination . Diagnosed cancer , treatment cancer within 3 year . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Chronic administration immunosuppressant immune modify drug within 6 month study enrolment plan administration study period . Receipt immunoglobulins and/or blood product within 3 month study enrolment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . An acute evolve neurological disorder history GuillainBarré syndrome . Administration vaccine within 30 day vaccination plan administration within first vaccination blood sample Day 42 within 30 day prior blood sample Day 182 , exception seasonal influenza vaccine . Administration seasonal influenza vaccine within 14 day vaccination Day 0 , plan administration within first vaccination blood sample Day 42 within 14 day prior blood sample Day 182 . Any known suspected allergy constituent influenza vaccine component use manufacturing process study vaccine ; history anaphylactictype reaction constituent influenza vaccine ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine test result prior time first vaccination . Lactating nursing female . Excessive underweight ( Body Mass Index [ BMI ] &lt; 18.5 ) excessive obesity ( BMI &gt; = 30 ) . Any condition , opinion investigator , prevents subject participate study . Clinically virologically confirm influenza infection within 6 month precede study start .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>influenza infection</keyword>
	<keyword>GSK Biologicals ' influenza vaccine GSK2340272A</keyword>
</DOC>